Exelixis Abandons Tissue Factor-Targeting ADC Due to Competition from Tivdak
Exelixis, tissue factor-targeting ADC, Tivdak, biotech, pharmaceuticals, drug development
FDA Approves Voranigo, the First Targeted Therapy for Grade 2 IDH-Mutant Glioma
Voranigo, FDA approval, targeted therapy, Grade 2 IDH-mutant glioma, brain tumor, Servier Pharmaceuticals, IDH1/IDH2 inhibitor
Unveiling the Top 11 Biotech Startups to Watch: Join Us for the Awards Gala in Boston
Biotech startups, Endpoints News, awards gala, Boston, biotech industry, innovation, healthcare
Pharma Campaign Contributions, Vaccine Hiccups, and Lykos’ Moment of Truth
Pharma campaign contributions, vaccine hiccups, Lykos Therapeutics, MDMA-assisted treatment, FDA approvals, Q2 earnings, biopharma challenges
Biopharma Layoff Tracker 2024: Precigen, Sumitomo, BMS and More Cut Staff
biopharma layoffs, Precigen, Sumitomo, Bristol Myers Squibb, biotech industry, job cuts, restructuring, pharmaceutical companies
Sangamo Secures $50M Upfront in Neurodegenerative Pact with Roche’s Genentech
Sangamo, Roche, Genentech, neurodegenerative, biotech, licensing deal, milestone payments, biobucks
GSK Secures Another Legal Victory in Latest Zantac Verdict
GSK, Zantac, legal victory, cancer claims, ranitidine, NDMA, FDA, pharmaceutical litigation
Sangamo Partners with Genentech for $1.9 Billion Neurology-Focused Deal Using Zinc Finger Technology
Sangamo, Genentech, zinc finger technology, neurology, Alzheimer’s disease, tau gene, biobucks, biopharma, gene therapy, Fabry disease
BioMarin Restricts Roctavian Sales to U.S., Germany, and Italy Amid Stagnant Sales
BioMarin, Roctavian, hemophilia A gene therapy, U.S., Germany, Italy, sales strategy, profitability, cost reduction
Mallinckrodt Sells Immunotherapy Business to CVC Capital for $925 Million
Mallinckrodt, CVC Capital, immunotherapy, Therakos, $925 million deal